Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-10-13
2009-10-27
Nguyen, Quang (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S456000, C435S320100
Reexamination Certificate
active
07608255
ABSTRACT:
Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.
REFERENCES:
patent: 5677178 (1997-10-01), McCormick
patent: 5846945 (1998-12-01), McCormick
patent: 6197293 (2001-03-01), Henderson
patent: 6254862 (2001-07-01), Little et al.
patent: 6627190 (2003-09-01), Wold et al.
patent: WO 98/39465 (1998-09-01), None
Smith et al., “Studies on the use of viruses in the treatment of carcinoma of the cervix,” Cancer 9: 1211-1218, 1956.
Barker et al., “Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral transfection and DNA transfection,”, Virol. 156: 107-121, 1987.
Bett et al., “DNA sequence of the deletion/insertion in early region 3 of Ad5 dl309,” Virus Res. 39: 75-82, 1995.
Decision on Appeal No. 2005-1444, Ex parte Wold et al., Board of Patent Appeals and Interferences rendered Jan. 26, 2006.
Decision on Request for Rehearing of Appeal No. 2005-1444, Ex parte Wold et al., Board of Patent Appeals and Interferences rendered Sep. 28, 2006.
Anderson et al., Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer,Gene Therapy, 6:854-864, 1999.
Anderson, “Human gene therapy,”Nature, 392:25-30, 1998.
Arai et al., “Gene transfer of Fas ligand induces tumor regression in vivo,”Proc. Natl. Acad. Sci. USA, 94:13862-13867, 1997.
Bett at al., “An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3,”Proc. Natl. Acad. Sci. USA, 91:8802-8806, 1994.
Bischoff et al., “An Adenovirus Mutant that Replicates Selectively in p53-Deficient Human Tumor Cells,”Science, 274:373-376, 1996.
Chakravarti et al., “A Viral Mechanism for Inhibition of p300 and PCAF Acetyltransferase Activity,”Cell, 96:393-403, 1999.
Curiel, “Strategies to Adapt Adenovirl Vectors for Targeted Delivery,”Ann NY Acad Sci, 886:158-171, 1999.
De-Chao et al., “The addition of Adenovirus Type 5 Region E3 Enable Calydon Virus 787 to Eliminate Distant Prostate Tumor Xenografts,”Cancer Research, 59:4200-4203, 1999.
DePinho, “The cancer-chromatin connection,”Nature, 391:533-536, 1998.
Doronin et al., “Adenovirus replication-competent, tumor-specific vectors that overexpress ADP,” Abstract for American Society of Gene Therapy Meeting,Molecular Therapy, 2000.
Doronin et al., “Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy,”J. Virol., 75:3314-3324, 2001.
Doronin et al., “Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein,”Journal of Virology, 74:6147-6155, 2000.
Elshami etal., “Treatment of Pleural Mesothelioma in an Immunocompetent Rat Model Utilizing Adenoviral Transfer of the Herpes Simplex Virus Thymidine Kinase Gene,”Human Gene Therapy, 7:141-148, 1996.
Felzmann et al., “Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1,”Gene Ther., 4:1322-1329, 1997.
Freytag et al., “A Novel Three-Pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide Bene, and Radiotherapy,”Human Gene Therapy, 9:1323-1333, 1998.
Geertsen et al., “The Presence of Human Coxsackievirus and Adenovirus Receptor Is Associated with Efficient Adenkovirus-Mediated Transgene Expression in Human Melanoma Cell Cultures,”Human Gene Therapy, 9:2363-2373, 1998.
Ghosh and Ghosh, “Role of the membrane anchoring and cytoplasmic domains in intracellular transport and localization of viral glycoproteins,”Biochem Cell Biol., 77:165-178, 1999.
Gomez-Navarro et al., “Gene Therapy for Cancer,” 1999,European Journal of Cancer, 35: 867-885, 1999.
Greenberg et al., “Liver-specific expression of the human factor VII gene,”Proc. Natl. Acad. Sci. USA, 92:12347-12351, 1995.
Hallenbeck at al., “A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma,”Human Gene Therapy, 10:1721-1733, 1999.
Hamamori et al., “Regulation of Histone Acetyltransferases p300 and PCAF by the bHLH Protein Twist and Adenoviral Oncoprotein ElA,” Cell, 96:405-413; 1999.
Harada et al., “p53-Independent and —Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication,”J. Virol, 73:5333-5344, 1999.
Harrod et al., “Lung-Specific Expression of Adenovirus E3-14.7K in Transgenic Mice Attenuates Adenoviral Vector-Mediated Lung Inflammation and Enhances Transgene Expression,”Human Gene Therapy, 9:1885-1898, 1998.
Hausmann et al., “Adenovirus Death Protein, a Transmembrane Protein Encoded in the E3 Region, Is Palmitoylated at the Cytoplasmic Tail,”Virology, 244:343-351, 1998.
Heise et al, “ONYX-O15, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents,”Nature Med., 3:639-645, 1997.
Hobbs et at, “Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment,”Proc. Natl., Acad. Sci., 95:4607-4612, 1998.
Howe et al., “Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis,”Proc. Natl. Acad. Sci., 87:5883-5887, 1990.
Jones et al., “Isolation of Adenovirus Type 5 Host Range Deletion Mutants Defective for transformation of Rat Embryo Cells,”Cell, 17:683-689, 1979.
Kim et al., “Replication-competent adenovirus anticancer vectors-radiotherapy synergy experiment in tissue culture phase,” ASTRO Conference, 1999 (abstract).
Kim et al., “Synergistic effects of specially designed replication competent adenovirus vector and radiotherapy,”Proceedings of the American Society for Therapeutic Radiology and Oncology 42ndAnnual Meeting, 2000.
Kuppuswamy et al., “Adenovirus death protein-expressing replication-competent vectors to treat cancer-preclinical studies,” Abstract to the 1999 meeting on programmed cell death at cold Spring Harbor Laboratory, Sep. 29, 1999.
Lazzaro et al., “The transcription factor TTF-1 is expressed at the onset of thyroid and lunc morphogenesis and in restricted regions of the foetal brain,”Development, 113:1093-1104, 1991.
Li et al, “Control of apoptosis and mitotic spindle checkpoint by survivin,”Nature, 396:580-584, 1998.
Li et al., “Loss of Adenoviral Receptor Expression in Human Bladder Cancer Cells: A Potential Impact on the Efficacy of Gene Therapy,”Cancer Research, 59:325-330, 1999.
Li et al., “Variability of Adenovirus Receptor Density Influences Gene Transfer Efficiency and Therapeutic Response in Head and Neck Cancer,”Clinical Cancer Research, 5:4175-4181, 1999.
Lubeck et al, “Immunogenicity of Recombinant Adenovirus-Human Immunodeficiency Virus Vaccines in Chimpanzees Following Intranasal Administration,”AIDS Res. Hum. Retroviruses, 10:1443-1449, 1994.
Jain, “Delivery of molecular and cellular medicine to solid tumors,”Journal of Controlled Release, 53:49-67, 1998.
Machemer et al., “Efficacy of a replicating adenovirus (K9TB) in human tumor xenograft mouse models,” American Society of Gene Therapy Meeting Abstract, Jun. 2001.
Massie et at, “Inducible Overexpression of a Toxic Protein by an Adenovirus Vector with a Tetracycline-Rugulatable Expression Cassett,”J. of Virol., 72:2289-2296, 1998.
Miller et at.,
Doronin Konstantin
Tollefson Ann E.
Toth Karoly
Wold William S. M.
Fulbright & Jaworski L.L.P.
Nguyen Quang
Saint Louis University
LandOfFree
Replication-competent anti-cancer vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Replication-competent anti-cancer vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Replication-competent anti-cancer vectors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4111771